Argitalpenak (50) Alina Lucica Boteanu argitalpenak

2024

  1. Cardiovascular risk in young people with childhood onset systemic lupus erythematosus

    The Lancet Rheumatology

  2. Clinical characteristics and prognostic factor in juvenile dermatomyositis: data of the Spanish registry

    Pediatric Rheumatology , Vol. 22, Núm. 1

  3. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis

    Rheumatology (United Kingdom), Vol. 63, Núm. 9, pp. 2535-2546

  4. Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: Preliminary results of an open-label, long-term extension study

    Annals of the Rheumatic Diseases

2023

  1. A child with targetoid facial papules and acral plaques

    Pediatric Dermatology

  2. Haematological and other manifestions in the presence of antiphospholipid antibodies in a multicentric paediatric cohort

    Clinical and experimental rheumatology, Vol. 41, Núm. 11, pp. 2331-2337

  3. Juvenile idiopathic arthritis in the young adult. Methodology, objectives, and initial data from the JUVENSER registry

    Reumatologia Clinica, Vol. 19, Núm. 6, pp. 328-333

  4. Severe COVID-19 in patients with immune-mediated rheumatic diseases: A stratified analysis from the SORCOM multicentre registry

    Modern rheumatology, Vol. 34, Núm. 1, pp. 97-105

  5. What drives the decision to optimise biological treatment in children and youngsters with juvenile idiopathic arthritis? A discrete-choice experiment

    Reumatologia Clinica, Vol. 19, Núm. 1, pp. 26-33

  6. What to Expect When Systemic Treatment in Juvenile Idiopathic Arthritis Is Withdrawn?

    The Journal of rheumatology, Vol. 50, Núm. 10, pp. 1326-1332

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study

    Rheumatology (Oxford, England), Vol. 62, Núm. 1, pp. 217-224

  3. Evaluation of flare rate and reduction strategies for bDMARDs in juvenile idiopathic arthritis: real world data from a single-centre cohort

    Rheumatology International, Vol. 42, Núm. 7, pp. 1133-1142

  4. Inmune-mediated inflammatory rheumatic diseases in transgender people: A scoping review

    Seminars in Arthritis and Rheumatism, Vol. 52

  5. Non-criteria manifestations in the presence of antiphospholipid antibodies in a paediatric cohort

    Rheumatology (Oxford, England), Vol. 61, Núm. 11, pp. 4465-4471

2021

  1. A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis

    Rheumatology (United Kingdom), Vol. 60, Núm. 6, pp. 2896-2905

  2. Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases

    Pediatric Rheumatology, Vol. 19, Núm. 1

  3. Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain

    Reumatologia Clinica, Vol. 17, Núm. 5, pp. 245-249

  4. Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis

    Arthritis Care and Research, Vol. 73, Núm. 9, pp. 1264-1274

  5. Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?

    Rheumatology (Oxford, England), Vol. 60, Núm. 11, pp. 5329-5336